



## Imugene Appoints Distinguished Scientists to Scientific Advisory Board

**Melbourne, 20 January 2014:** Australian biopharmaceutical company Imugene (ASX;IMU) today announced the appointment of Univ. Professor Dr Dr.h.c. Christoph Zielinski and Univ. Professor Dr Ursula Wiedermann MD, PhD, to the Company's Scientific Advisory Board.

"We are extremely pleased that two scientists of such substantial international calibre, Professors Zielinski and Wiedermann, have joined the Imugene Scientific Advisory Board. They are both internationally recognized as leaders in oncology, vaccinology and immunology. Together with their colleagues, both have been instrumental in the advancement of Imugene's immunotherapy candidate "HER-Vaxx" " said Dr Nick Ede, Executive Director Imugene.

Professor Zielinski is Director of the Clinical Division of Oncology and Chairman of the Department of Medicine at the Medical University of Vienna, Austria. He serves as coordinator of the Comprehensive Cancer Centre at the Medical University of Vienna ([www.ccc.ac.at](http://www.ccc.ac.at)) and the General Hospital in Vienna, Austria and is President of the Central European Cooperative Oncology Group (CECOG, [www.cecog.org](http://www.cecog.org)). He has published more than 420 original research papers and reviews in peer-reviewed journals.

Professor Wiedermann is Professor of Vaccinology and Head of the Institute of Specific Prophylaxis and Tropical Medicine of the Medical University Vienna. Currently she also has an appointment as Visiting Professor at the University in Göteborg, Sweden. She has more than 100 peer-reviewed publications and is frequently performing presentations at national and international conferences. Professor Wiedermann was the Principal Investigator for the preclinical development of HER-Vaxx and together with Prof. Zielinski's Division the Phase I clinical trial of HER-Vaxx in metastatic breast cancer patients was performed. Furthermore she has led the design of the Phase II study for gastric cancer due to commence in 2015.

For more extensive bibliography's please visit Imugene's website, [www.imugene.com](http://www.imugene.com).

**-ends**

### **Contact :**

Dr Nick Ede, Imugene on 0400 642 254 or [nede\[at\]imugene.com](mailto:nede[at]imugene.com)

### **Media contact:**

Dr Douglas Pretsell, College Hill – +61 3 9657 0706 / [douglas.pretsell\[at\]collegehill.com](mailto:douglas.pretsell[at]collegehill.com)

**About Imugene:** Imugene (ASX; IMU) is an oncology focused biopharmaceutical company developing clinical immunotherapeutics to advance cancer care. The Company's lead product is HER-Vaxx, a proprietary immunotherapeutic vaccine that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit [www.imugene.com](http://www.imugene.com)

**Imugene Limited**

**A.C.N: 009 179 551**

**Suite 1, 1233 High Street, Armadale, VIC, 3142**

**Phone: 03 9824 5254 Fax: 03 9822 7735**